Posttransplant Blockade of CXCR4 Improves Leukemia Complete Remission Rates and Donor Stem Cell Engraftment without Aggravating GVHD

The authors found that posttransplant treatment with the CXCR4 antagonist AMD3100 significantly improved the eradication of leukemia cells in the bone marrow in patient-derived xenograft mice grafted with B cell acute lymphoblastic leukemia cells from multiple patients.